| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (groß) | News + Adhoc | Bilanz/GuV | Termine | Zertifikate | Depot |
| Times + Sales | Chart-Analyse | Analysen | Dividende/HV | Profil | Optionsscheine | Watchlist |
| Börsenplätze | Chartvergleich | Kursziele | Vergleich | Insidertrades | Knock-outs | myHome |
| Orderbuch | Realtime Stuttgart | RSS Feed | im Forum | Fonds | Senden/Drucken | |
| Historisch | Realtime Push | myNews neu | Ausblick | IR-Daten | Anleihen | handeln |
Roche zu myNews hinzufügen Was ist das?
Dynex Capital, Inc. (NYSE: DX) reported diluted earnings per common share of $0.34 for the second quarter of 2011 versus $0.38 diluted earnings per common share for the second quarter of 2010. The Company also reported book value per common share of $9.59 at June 30, 2011 versus $9.51 at March 31, 2011 and $9.64 at December 31, 2010. Other highlights for the quarter include:
As previously announced, the Company's quarterly conference call to discuss the second quarter results is today, July 28, 2011 at 11:00 a.m. ET. Interested investors may access the call by dialing 1-877-317-6789 or by webcast over the internet at www.dynexcapital.com through a link provided under "Investor Relations/IR Highlights.”
Thomas Akin, Chairman and Chief Executive Officer, commented, "We invested the remaining proceeds from our March 2011 capital raise during the second quarter and stand fully invested at June 30, 2011. Our overall leverage is now at 5.9 times equity capital, which is within our target leverage range. Most of the investment activity during the second quarter was in Hybrid Agency ARMs and consequently the investment portfolio is now more heavily weighted to Agency MBS versus our targeted mix of 60% Agency and 40% non-Agency investments. We have recently seen attractive risk-adjusted opportunities in non-Agency investments and expect to deploy capital in these investments over the balance of the year as we move toward our targeted investment mix. That said, we are pleased with the investments we added during the second quarter given our strong earnings and growth in book value per common share during the quarter. Our net interest spread is a solid 2.45%, our leverage is at our target, and our portfolio remains extremely high quality with 94% either Agency or 'AAA'-rated.”
Results of Operations
Net interest income increased to $15.0 million for the second quarter of 2011 versus $7.9 million for the second quarter of 2010. Most of the increase is attributable to growth in average interest earning investments to $2,357.3 million for the second quarter of 2011 from $941.0 million for the second quarter of 2010, partially offset by a decline in the yield on interest earning assets. Amortization of investment purchase premium for the second quarter of 2011 was $6.6 million versus $1.9 million for the second quarter of 2010 and $3.9 million for the first quarter of 2011, reflecting the growing investment portfolio and the higher cost basis of recently added Agency MBS.
Net portfolio interest spread for the second quarter of 2011 was 2.45% versus 2.75% for the second quarter of 2010 and 2.68% for the first quarter of 2011. The net portfolio interest spread of 2.45% is the difference between the yield on the Company's interest-earning investment portfolio of 3.61% and its cost of funds of 1.16%. The net portfolio interest spread has decreased from prior quarters as a result of the overall decline in investment yields due to the addition of lower yielding Hybrid Agency ARMs to the investment portfolio with proceeds from the Company's capital raise in March 2011. During the second quarter of 2011 the yield on these investments was 3.18%. Cost of funds declined 6 basis points for the second quarter of 2011 compared to the first quarter of 2011 from continued improvement in repurchase agreement borrowing costs.
Gain on sale of investments for the second quarter of 2011 of $0.7 million resulted primarily from the sale of short-reset Agency Hybrid ARMs with a par value of $30.8 million. The Company selectively sold these lower yielding investments and redeployed the proceeds in higher yielding non-Agency investments.
Agency MBS Investments
During the quarter, the Company purchased $432.9 million in Hybrid Agency ARMS with a weighted average coupon of 5.07%, a weighted average months-to-reset of 49 months, and weighted average purchase price of 106.8 as of June 30, 2011. The Company also purchased $24.2 million in CMBS I/O's during the second quarter.
Bryon Boston, Chief Investment Officer, stated, "With respect to Agency RMBS, we continue to believe that the long-term structural shift in the mortgage market toward tighter underwriting standards has reduced the probability of an extreme prepayment event, thus improving the risk-return profile of these securities."
As of June 30, 2011, the Company had $1,566.9 million in Hybrid Agency ARMs with a weighted average months-to-reset of 40 months, $339.4 million in Agency ARMs with a weighted average months-to-reset of 8 months, and $275.6 million in fixed rate Agency CMBS. The Company's Agency MBS at June 30, 2011 consisted of $1,541.2 million in Fannie Mae Agency MBS and $640.7 million in Freddie Mac Agency MBS. The following table summarizes certain information about the Company's Agency MBS investments for the periods presented:
| (amounts in thousands) |
Quarter ended
June 30, 2011 |
Quarter ended
March 31, 2011 |
Quarter ended
June 30, 2010 |
||||||||||||
| Weighted average annualized yield for the period | 3.17 | % | 3.32 | % | 3.45 | % | |||||||||
| Weighted average annualized cost of funds including interest rate swaps for the period | (0.81 | )% | (0.87 | )% | (0.63 | )% | |||||||||
| Net interest spread for the period | 2.36 | % | 2.45 | % | 2.82 | % | |||||||||
| Average balance for the period | $ | 1,966,814 | $ | 1,377,160 | $ | 559,789 | |||||||||
| CPR for the period | 23.2 | % | 21.9 | % | 33.9 | % | |||||||||
| Weighted average coupon | 4.65 | % | 4.59 | % | 4.58 | % | |||||||||
| Weighted average months-to-reset on ARMs and Hybrid ARMs, period end | 35 | 32 | 19 | ||||||||||||
| Amortized cost (as a % of par), period end | |||||||||||||||
| Agency RMBS | 105.7 | % | 105.0 | % | 104.7 | % | |||||||||
| Agency CMBS (excluding IOs) | 108.8 | % | 109.0 | % | 109.8 | % | |||||||||
| Weighted average repurchase agreement original term to maturity (days), period end | 50 | 50 | 45 | ||||||||||||
Non-Agency Investments
As of June 30, 2011, the fair value of the Company's non-Agency CMBS and RMBS was $266.8 million and $10.4 million, respectively. Below is certain information about the Company's non-Agency MBS and securitized mortgage loan portfolio as of and for the quarter ended June 30, 2011:
| (amounts in thousands) | CMBS | RMBS | Securitized loans | ||||||||||||
| Principal balance | $ | 250,817 | $ | 11,561 | $ | 129,049 | |||||||||
| Amortized cost basis, net of reserves | $ | 253,853 | $ | 10,513 | $ | 130,925 | |||||||||
| Average balance for the period, amortized cost | $ | 238,562 | $ | 12,671 | $ | 138,137 | |||||||||
| Weighted average annualized yield for the period | 6.03 | % | 6.23 | % | 5.51 | % | |||||||||
| Weighted average annualized cost of funds | (3.16 | )% | (1.19 | )% | (3.27 | )% | |||||||||
| Net interest spread for the period | 2.87 | % | 5.04 | % | 2.24 | % | |||||||||
| Amortized cost (excluding reserves) as a % of par | 97.1 | % | 90.9 | % | 100.4 | % | |||||||||
| Percentage 'AAA' and 'AA'-rated | 75.7 | % | 43.5 | % | 62.0 | % | |||||||||
| Percentage below 'AA'-rated | 24.3 | % | 56.5 | % | 38.0 | % | |||||||||
Seriously delinquent loans (loans 60+ days past due) in the Company's securitized mortgage loan portfolio totaled $25.2 million as of June 30, 2011, $24.6 million as of March 31, 2011, and $17.7 million as of December 31, 20 10. Three seriously delinquent commercial loans totaling $2.4 million were liquidated during the second quarter of 2011 at no additional loss to the Company after consideration of the associated allowance for loan losses. In addition, three seriously delinquent commercial loans were liquidated subsequent to the end of the second quarter with a total combined unpaid principal balance of $4.9 million. As of June 30, 2011, the allowance for loan losses was $3.3 million for the Company's securitized mortgage loan portfolio.
Hedging Activities
During the second quarter of 2011, the Company entered into $135 million of pay-fixed interest rate swaps with an average rate of 1.20% and original weighted average maturity of 41 months. As of June 30, 2011, the Company had a total of $1,007 million in pay-fixed interest rate swaps with a weighted average rate of 1.57% and a weighted average remaining maturity of 38 months. Of this amount, $27 million are considered trading instruments and have a weighted average rate of 2.88% and weighted average remaining maturity of 63 months and are intended to offset market value changes of Agency CMBS with a par value of $22.5 which are also designated as trading instruments. The remaining interest rate swaps are being used to hedge the Company's exposure to changes in LIBOR for its repurchase agreement borrowings.
Shareholders' Equity and Book Value per Common Share
Shareholders' equity was $386.9 million as of June 30, 2011 versus $383.5 million at March 31, 2011 and $292.4 million as of December 31, 2010. The Company's common shares outstanding at June 30, 2011 were 40,343,159 versus 40,318,159 at March 31, 2011 and 30,342,897 at December 31, 2010.
The following table summarizes the allocation of the Company's shareholders' equity as of June 30, 2011 and the net earnings contribution for the quarters indicated to each component of the Company's balance sheet:
| (amounts in thousands) |
Asset Carrying Basis |
Associated Financing(1)/ Liability Carrying Basis |
Allocated Shareholders' Equity |
% of Shareholders' Equity |
2Q11 Net Interest Income Contribution |
1Q11 Net Interest Income Contribution |
|||||||||||||
| Agency RMBS | $ | 1,906,300 | $ | 1,728,495 | $ | 177,805 | 46.0 | % | $ | 10,099 | $ | 7,977 | |||||||
| Agency CMBS | 275,550 | 192,652 | 82,898 | 21.4 | % | 1,597 | 1,268 | ||||||||||||
| Non-Agency RMBS | 10,442 | 7,693 | 2,749 | 0.7 | % | 165 | 167 | ||||||||||||
| Non-Agency CMBS | 266,753 | 218,442 | 48,311 | 12.5 | % | 2,002 | 1,931 | ||||||||||||
| Securitized mortgage loans (2) | 130,925 | 91,950 | 38,975 | 10.1 | % | 940 | 1,101 | ||||||||||||
| Other investments (2) | 1,127 | — | 1,127 | 0.3 | % | 29 | 33 | ||||||||||||
| Derivative instruments(3) | 432 | 13,295 | (12,863 | ) | (3.3 | )% | — | — | |||||||||||
| Cash and cash equivalents | 33,975 | — | 33,975 | 8.8 | % | 1 | 4 | ||||||||||||
| Other assets/other liabilities | 31,199 | 17,316 | 13,883 | 3.6 | % | — | — | ||||||||||||
| $ | 2,656,703 | $ | 2,269,843 | $ | 386,860 | 100.0 | % | $ | 14,833 | $ | 12,481 | ||||||||
|
(1) |
Associated financing for investments includes repurchase agreements, securitization financing issued to third parties and TALF financing (the latter two of which are presented on the Company's balance sheet as "non-recourse collateralized financing”). Associated financing for hedging instruments represents the fair value of the interest rate swap agreements in a liability position. |
|
|
(2) |
Net interest income contribution amount is after provision for loan losses. |
|
|
(3) |
Net interest income contribution from derivative instruments designated as hedges of repurchase agreement financing is included within net interest income contribution amounts for Agency RMBS, Agency CMBS, and non-Agency CMBS. Derivative instruments designated as trading do not have an effect on net interest income as changes in their fair value are included on the statement of income in "fair value adjustments, net”. |
|
Company Description
Dynex Capital, Inc. is an internally managed real estate investment trust, or REIT, which invests in mortgage assets on a leveraged basis. The Company invests in Agency and non-Agency RMBS and CMBS. The Company also has investments in securitized single-family residential and commercial mortgage loans originated by the Company from 1992 to 1998. Additional information about Dynex Capital, Inc. is available at www.dynexcapital.com.
Note: This release contains "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe,” "expect,” "forecast,” "anticipate,” "estimate,” "project,” "plan,” and similar expressions identify forward-looking statements that are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements in this release include, without limitation, statements regarding future interest rates, our views on expected characteristics of future investment environments, our future investment strategies, our future leverage levels and financing strategies, and the expected performance of our investment portfolio and certain of our investments. The Company's actual results and timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements as a result of unforeseen external factors. These factors may include, but are not limited to, changes in general economic and market conditions, including the ongoing volatility in the credit markets which impacts asset prices and the cost and availability of financing, defaults by borrowers, availability of suitable reinvestment opportunities, variability in investment portfolio cash flows, fluctuations in interest rates, fluctuations in property capitalization rates and values of commercial real estate, defaults by third-party servicers, prepayments of investment portfolio assets, other general competitive factors, uncertainty around government policy, the impact of regulatory changes, including the Emergency Economic Stabilization Act of 2008 and the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the full impacts of which are unknown at this time, and the impact of Section 404 of the Sarbanes-Oxley Act of 2002. For additional information on risk factors that could affect the Company's forward-looking statements, see the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and other reports filed with and furnished to the Securities and Exchange Commission.
|
DYNEX CAPITAL, INC. |
||||||||||
|
Consolidated Balance Sheets |
||||||||||
|
(Thousands except per share data) |
||||||||||
| June 30, 2011 | December 31, 2010 | |||||||||
| ASSETS | (unaudited) | |||||||||
| Agency MBS | $ | 2,181,850 | $ | 1,192,579 | ||||||
| Non-Agency MBS | 277,195 | 267,356 | ||||||||
| Securitized mortgage loans, net | 130,925 | 152,962 | ||||||||
| Other investments, net | 1,127 | 1,229 | ||||||||
| 2,591,097 | 1,614,126 | |||||||||
| Cash and cash equivalents | 33,975 | 18,836 | ||||||||
| Derivative assets | 432 | 692 | ||||||||
| Principal receivable on investments | 14,402 | 3,739 | ||||||||
| Accrued interest receivable | 11,380 | 6,105 | ||||||||
| Other assets, net | 5,417 | 6,086 | ||||||||
| Total assets | $ | 2,656,703 | $ | 1,649,584 | ||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||
| Liabilities: | ||||||||||
| Repurchase agreements | $ | 2,133,249 | $ | 1,234,183 | ||||||
| Non-recourse collateralized financing | 105,983 | 107,105 | ||||||||
| Derivative liabilities | 13,295 | 3,532 | ||||||||
| Accrued interest payable | 1,437 | 1,079 | ||||||||
| Accrued dividends payable | 10,893 | 8,192 | ||||||||
| Other liabilities | 4,986 | 3,136 | ||||||||
| Total liabilities | 2,269,843 | 1,357,227 | ||||||||
| Shareholders’ equity: | ||||||||||
|
Common stock, par value $.01 per share, 100,000,000 shares
authorized; 40,343,159 and 30,342,897 shares issued and outstanding, respectively |
403 | 303 | ||||||||
| Additional paid-in capital | 633,969 | 538,304 | ||||||||
| Accumulated other comprehensive income | 6,699 | 10,057 | ||||||||
| Accumulated deficit | (254,211 | ) | (256,307 | ) | ||||||
| Total shareholders' equity | 386,860 | 292,357 | ||||||||
| Total liabilities and shareholders’ equity | $ | 2,656,703 | $ | 1,649,584 | ||||||
| Book value per common share | $ | 9.59 | $ | 9.64 | ||||||
| DYNEX CAPITAL, INC. | ||||||||||||||||
|
Consolidated Statements of Operations |
||||||||||||||||
|
(Thousands except per share data) |
||||||||||||||||
|
(unaudited) |
||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2011 | 2010 | 2011 | 2010 | |||||||||||||
| Interest income: | ||||||||||||||||
| Agency MBS | $ | 15,244 | $ | 4,610 | $ | 26,762 | $ | 9,478 | ||||||||
| Non-Agency MBS | 3,830 | 3,741 | 7,521 | 6,241 | ||||||||||||
| Securitized mortgage loans | 1,961 | 3,355 | 4,180 | 6,978 | ||||||||||||
| Other investments | 29 | 32 | 62 | 64 | ||||||||||||
| Cash and cash equivalents | 1 | 2 | 5 | 5 | ||||||||||||
| 21,065 | 11,740 | 38,530 | 22,766 | |||||||||||||
| Interest expense: | ||||||||||||||||
| Repurchase agreements | 4,760 | 1,362 | 8,188 | 2,625 | ||||||||||||
| Non-recourse collateralized financing | 1,272 | 2,446 | 2,578 | 5,013 | ||||||||||||
| 6,032 | 3,808 | 10,766 | 7,638 | |||||||||||||
| Net interest income | 15,033 | 7,932 | 27,764 | 15,128 | ||||||||||||
| Provision for loan losses | (200 | ) | (150 | ) | (450 | ) | (559 | ) | ||||||||
| Net interest income after provision for loan losses | 14,833 | 7,782 | 27,314 | 14,569 | ||||||||||||
| Gain on sale of investments, net | 742 | 716 | 742 | 794 | ||||||||||||
| Fair value adjustments, net | 132 | 71 | 5 | 153 | ||||||||||||
| Other income, net | 142 | 555 | 186 | 1,224 | ||||||||||||
| General and administrative expenses: | ||||||||||||||||
| Compensation and benefits | (1,209 | ) | (870 | ) | (2,341 | ) | (1,842 | ) | ||||||||
| Other general and administrative | (1,046 | ) | (987 | ) | (2,032 | ) | (2,094 | ) | ||||||||
| Net income | 13,594 | 7,267 | 23,874 | 12,804 | ||||||||||||
| Preferred stock dividends | — | (1,003 | ) | — | (2,005 | ) | ||||||||||
| Net income to common shareholders | $ | 13,594 | $ | 6,264 | $ | 23,874 | $ | 10,799 | ||||||||
| Weighted average common shares: | ||||||||||||||||
| Basic | 40,333 | 15,122 | 36,763 | 14,668 | ||||||||||||
| Diluted | 40,334 | 19,347 | 36,765 | 18,893 | ||||||||||||
| Net income per common share: | ||||||||||||||||
| Basic | $ | 0.34 | $ | 0.41 | $ | 0.65 | $ | 0.74 | ||||||||
| Diluted | $ | 0.34 | $ | 0.38 | $ | 0.65 | $ | 0.68 | ||||||||
| Dividends declared per common share | $ | 0.27 | $ | 0.23 | $ | 0.54 | $ | 0.46 | ||||||||
| Geben Sie jetzt einen Kommentar zu diesem Artikel ab. |
07.05.12 | Börsen in Europa Schluss: Mehrheitlich im Plus (Aktiencheck) |
07.05.12 | Börsen in Europa am Mittag: Etwas freundlicher, Roche unter Druck (Aktiencheck) |
07.05.12 | Roche: Entwicklung von Medikament Dalcetrapib nach erfolgloser Studie gestoppt (Aktiencheck) |
04.05.12 | Zertifikat für profitable Pillen (finanzen.net) |
12.04.12 | Börsen in Europa Schluss: Kurse drehen ins Plus, Roche nach Umsatzzahlen fester (Aktiencheck) |
12.04.12 | Börsen in Europa am Mittag: Stimmung trübt ein, Royal Dutch Shell unter Druck (Aktiencheck) |
12.04.12 | Börsen in Europa am Morgen: Leichte Zugewinne, Roche nach Umsatzzahlen im Blick (Aktiencheck) |
12.04.12 | Roche: Starker Franken belastet Umsatzentwicklung im ersten Quartal (Aktiencheck) |
| Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv |
07.05.12 | Börsen in Europa Schluss: Mehrheitlich im Plus (Aktiencheck) |
07.05.12 | Börsen in Europa am Mittag: Etwas freundlicher, Roche unter Druck (Aktiencheck) |
07.05.12 | Roche: Entwicklung von Medikament Dalcetrapib nach erfolgloser Studie gestoppt (Aktiencheck) |
04.05.12 | Zertifikat für profitable Pillen (finanzen.net) |
12.04.12 | Börsen in Europa Schluss: Kurse drehen ins Plus, Roche nach Umsatzzahlen fester (Aktiencheck) |
12.04.12 | Börsen in Europa am Mittag: Stimmung trübt ein, Royal Dutch Shell unter Druck (Aktiencheck) |
12.04.12 | Börsen in Europa am Morgen: Leichte Zugewinne, Roche nach Umsatzzahlen im Blick (Aktiencheck) |
12.04.12 | Roche: Starker Franken belastet Umsatzentwicklung im ersten Quartal (Aktiencheck) |
09.06.11 | Vereinbarung zwischen Roche und UCLA ermöglicht Stammzell- und Krebsforschern frühen Zugang zu modernsten Technologien für die medizinische Forschung (Businesswire) |
07.05.12 | Roche: Entwicklung von Medikament Dalcetrapib nach erfolgloser Studie gestoppt (Aktiencheck) |
07.05.12 | Roche: Entwicklung von Medikament Dalcetrapib nach erfolgloser Studie gestoppt (Aktiencheck) |
| Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar |
04.05.12 | Zertifikat für profitable Pillen (finanzen.net) |
07.05.12 | Roche: Entwicklung von Medikament Dalcetrapib nach erfolgloser Studie gestoppt (Aktiencheck) |
07.05.12 | Börsen in Europa Schluss: Mehrheitlich im Plus (Aktiencheck) |
07.05.12 | Börsen in Europa am Mittag: Etwas freundlicher, Roche unter Druck (Aktiencheck) |
04.05.12 | Zertifikat für profitable Pillen (finanzen.net) |
07.05.12 | Roche: Entwicklung von Medikament Dalcetrapib nach erfolgloser Studie gestoppt (Aktiencheck) |
07.05.12 | Börsen in Europa Schluss: Mehrheitlich im Plus (Aktiencheck) |
07.05.12 | Börsen in Europa am Mittag: Etwas freundlicher, Roche unter Druck (Aktiencheck) |
| Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar |
| Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar |
| Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar |
| Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar |
Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen
Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen
vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden
| 17:05 Uhr | Roche buy | Deutsche Bank AG | |
| 07.05.12 | Roche buy | Vontobel Research | |
| 16.04.12 | Roche halten | Hamburger Sparkasse AG (Haspa) | |
| 13.04.12 | Roche outperform | Exane-BNP Paribas SA | |
| 12.04.12 | Roche outperform | Cheuvreux SA |
| 17:05 Uhr | Roche buy | Deutsche Bank AG | |
| 07.05.12 | Roche buy | Vontobel Research | |
| 13.04.12 | Roche outperform | Exane-BNP Paribas SA | |
| 12.04.12 | Roche outperform | Cheuvreux SA | |
| 05.04.12 | Roche outperform | Credit Suisse Group |
| 16.04.12 | Roche halten | Hamburger Sparkasse AG (Haspa) | |
| 11.04.12 | Roche neutral | Nomura | |
| 30.03.12 | Roche neutral | WestLB AG | |
| 14.02.12 | Roche neutral | Citigroup Corp. | |
| 08.02.12 | Roche halten | Hamburger Sparkasse AG (Haspa) |
| 17.10.07 | Roche reduzieren | Independent Research GmbH | |
| 14.08.07 | Roche reduzieren | Independent Research GmbH | |
| 19.07.07 | Roche reduzieren | Independent Research | |
| 12.07.07 | Roche reduzieren | Independent Research | |
| 19.04.07 | Roche reduzieren | Independent Research |
Alle: Alle Empfehlungen
Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
| Roche Holding AG (Inhaberaktie) | 133,31 | -0,86% |
| 21.05.2012 | Die wertvollsten Fußball-Klubs der Welt |
| 24.04.2012 | Die besten Chefs der Welt |
| 12.04.2012 | Welche DAX-Konzerne ihre Anleger überschütten |
| 23.04.2012 | Mit diesen Autos greifen die Deutschen in China an |
| 29.05.2012 | Geheime Einblicke in den Kommunismus |
